Risk factors

What each company says could go wrong in its 10-K, and what changed since last year: the risks added, dropped and rewritten.

7,691 annual reports · 4,011 companies

Readings are automated and can be wrong; check the filing for the exact wording.

Older filings

Page 127 of 641 · 7,691 filings

  • Lifetime Brands (LCUT) FY2025 10-K risk factors
    40 risks3 new3 dropped16 reworded

    Lifetime Brands faces significant earnings pressure from U.S.-China tariff volatility and shifting consumer demand, leading to a $33.2 million goodwill write-down.

    Filed Mar 12, 2026
  • loanDepot (LDI) FY2025 10-K risk factors
    66 risks4 new8 dropped22 reworded

    loanDepot faces new liquidity risks from un-cleared derivatives and margin calls with hedging counterparties.

    Filed Mar 12, 2026
  • Lisata Therapeutics (LSTA) FY2025 10-K risk factors
    82 risks7 new5 dropped12 reworded

    Lisata added a merger agreement risk with Kuva and updated going concern warnings. Cash reserves stand at $16.0 million.

    Filed Mar 12, 2026
  • Lyell Immunopharma (LYEL) FY2025 10-K risk factors
    57 risks8 new13 dropped32 reworded

    Lyell is advancing cell therapy candidates like ronde-cel and LYL273 while managing clinical, manufacturing, and collaboration risks.

    Filed Mar 12, 2026
  • MBX Biosciences (MBX) FY2025 10-K risk factors
    107 risks4 new2 dropped11 reworded

    MBX reported widening net losses of $87.0 million in 2025 compared to $61.9 million in 2024, pushing its accumulated deficit to $224.5 million. The company added new risks covering capital raising constraints, third-party manufacturing supply chain disruptions from international trade and tariffs, and environmental, social, and governance compliance burdens.

    Filed Mar 12, 2026
  • Seres Therapeutics (MCRB) FY2025 10-K risk factors
    82 risks8 new14 reworded

    Funding pressure remains central: Seres has $45.8 million cash, expects funding after Q3 2026, and discloses substantial going-concern doubt.

    Filed Mar 12, 2026
  • Mineralys Therapeutics (MLYS) FY2025 10-K risk factors
    67 risks9 new6 dropped11 reworded

    Mineralys added risks concerning clinical trial adverse events, tariffs on API materials, patent validity challenges, data privacy compliance, and third-party license interpretation disputes. The company updated references from Mitsubishi to Tanabe regarding its exclusive license for lorundrostat.

    Filed Mar 12, 2026
  • Mach Natural Resources (MNR) FY2025 10-K risk factors
    90 risks6 new3 dropped11 reworded

    Mach Natural Resources updated its credit facility debt figures and general partner ownership stakes.

    Filed Mar 12, 2026
  • Mid Penn Bancorp (MPB) FY2025 10-K risk factors
    36 risks4 new12 dropped11 reworded

    Mid Penn expanded operations via mergers, specifically integrating William Penn and 1st Colonial, introducing integration and cost risks.

    Filed Mar 12, 2026
  • Merlin (MRLN) FY2025 10-K risk factors
    63 risks

    Merlin is a SPAC focused on closing its approved business combination, with shareholder redemptions and transaction funding dominating near-term risk.

    Filed Mar 12, 2026
  • MVB Financial (MVBF) FY2025 10-K risk factors
    42 risks3 new3 dropped5 reworded

    Real estate loan concentration increased to 79.9%, while on-balance sheet gaming deposits dropped from $227.6 million to $184.3 million. Goodwill decreased significantly to $1.2 million.

    Filed Mar 12, 2026
  • Nephros (NEPH) FY2025 10-K risk factors
    24 risks2 new5 reworded

    Nephros highlights tariff risks affecting EU suppliers of filtration materials following Supreme Court rulings on IEEPA.

    Filed Mar 12, 2026

Companies covered

4,011 companies

371 more under A